<?xml version="1.0" encoding="UTF-8"?>
<ref id="bb0595">
 <element-citation publication-type="journal" id="rf0595">
  <person-group person-group-type="author">
   <name>
    <surname>Uehara</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Hayden</surname>
    <given-names>F.G.</given-names>
   </name>
   <name>
    <surname>Kawaguchi</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Omoto</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Hurt</surname>
    <given-names>A.C.</given-names>
   </name>
   <name>
    <surname>De Jong</surname>
    <given-names>M.D.</given-names>
   </name>
   <span class="x" xmlns="http://www.w3.org/1999/xhtml">â€¦</span>
   <name>
    <surname>Kida</surname>
    <given-names>H.</given-names>
   </name>
  </person-group>
  <article-title>(2019). Treatment-emergent influenza variant viruses with reduced Baloxavir susceptibility: Impact on clinical and Virologic outcomes in uncomplicated influenza</article-title>
  <source>
   <italic>The Journal of Infectious Diseases</italic>
  </source>
  <volume>221</volume>
  <issue>3</issue>
  <year>2020 Jan 14</year>
  <fpage>346</fpage>
  <lpage>355</lpage>
  <pub-id pub-id-type="pmid">31309975</pub-id>
 </element-citation>
</ref>
